Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
At this time, Lilly has not studied the use of ixekizumab in patients with coronavirus disease 2019 (COVID-19) nor in patients at risk of contracting COVID-19.
Specific information related to risk of coronavirus infection in patients treated with ixekizumab is not available.
COVID-19 is an active respiratory infection, which is typically mild and may also lead to acute respiratory distress syndrome which can be lethal. Ixekizumab should not be used during active COVID-19 infection and may be resumed after medical consultation and infection is resolved.1
Ixekizumab Treatment in Patients with Suspected or Confirmed COVID-19 and Initiation of Ixekizumab in High Risk Areas
If COVID-19 is confirmed, ixekizumab should be immediately discontinued and may be resumed after medical consultation and infection is resolved.1
If COVID-19 infection is suspected and signs and symptoms of acute infection occur, the patient should consult with their healthcare provider and seek medical advice for guidance on continuing and initiating ixekizumab treatment.1
Infectious Disease Resources
For the most current information regarding the coronavirus, please refer to the websites of local health authorities and/or WHO at WHO Coronavirus disease (COVID-19) outbreak.
Contraindication and Warning
Ixekizumab is contraindicated in patients with clinically important active infections (e. g. active tuberculosis).2
Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.
Ixekizumab should be used with caution in patients with clinically important chronic infection. If such an infection develops, monitor carefully and discontinue ixekizumab if the patient is not responding to standard therapy or the infection becomes serious. Ixekizumab should not be resumed until the infection resolves.2
Infections as Adverse Drug Reactions of Ixekizumab
Infections belong to the known adverse drug reactions of ixekizumab:
upper respiratory tract infection (including nasopharyngitis and upper respiratory tract infection)
herpes simplex (mucocutaneous - defined as events with the preferred terms Oral herpes, Herpes simplex, Genital herpes, Herpes dermatitis, and Genital herpes simplex)
oral candidiasis (defined as events with the preferred terms oral candidiasis and oral fungal infection)
cellulitis (includes staphylococcal and external ear cellulitis, and erysipelas)2
*Adverse drug reactions in patients treated with ixekizumab in the plaque psoriasis and psoriatic arthritis clinical trials were similar with the exception of the frequencies of influenza (common) and conjunctivitis (common) in the psoriatic arthritis clinical trials
Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2
Ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.2
Lilly = Eli Lilly and Company
WHO = World Health Organization
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2020 M02 25